Altered Pharmacokinetics and Metabolism of Valproate after Replacement of Conventional Valproate with the Slow‐Release Formulation in Epileptic Patients
Authors:
Open Access
- 1 March 2002
- journal article
- clinical trial
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 90 (3) , 135-138
Abstract
Altered metabolism of valproate has been suggested as the mechanism of teratogenicity and hepatotoxicity of valproate. This study aimed at examining whether pharmacokinetics of a slow‐release formulation of valproate affects valproate metabolism. Thirty‐one epileptic patients were treated with fixed‐doses of conventional valproate for at least 2 months. Thereafter, the drug was replaced with the same doses of slow‐release formulation of valproate for 2 months. Blood samplings for determination of valproate and its metabolites by gas chromatography‐mass spectrometry were performed at three time‐points (just before morning dose and at 1 and 5 hr after morning dose) during both treatment phases. There was a significant difference (P<0.005) in the mean serum concentration (±S.D.) of valproate after 1 hr between conventional valproate (63.1±27.9 μg/ml) and slow‐release formulation of valproate (45.7±19.5 μg/ml). Mean serum concentrations (±S.D.) of 4‐en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow‐release formulation of valproate (4‐en: 29.5±14.0→23.0±15.3 ng/ml, 3‐OH: 488.5±234.0→419.6±171.1 ng/ml, 4‐OH: 404.3±124.7→342.8±147.6 ng/ml, 5‐OH: 102.8±54.4→81.0±43.6 ng/ml). The present study suggests that smaller diurnal fluctuations in valproate concentrations during treatment with slow‐release formulation of valproate result in decreased formations of minor metabolites including 4‐en, the most toxic metabolite.Keywords
This publication has 16 references indexed in Scilit:
- Associations Between Risk Factors for Valproate Hepatotoxicity and Altered Valproate MetabolismEpilepsia, 1992
- Teratogenicity of Antiepileptic Drugs: Analysis of Possible Risk FactorsEpilepsia, 1988
- Valproic acid hepatic fatalitiesNeurology, 1987
- Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acidThe Journal of Pediatrics, 1986
- Altered metabolic profiles of valproic acid in a patient with Reye's syndromeClinica Chimica Acta, 1985
- The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. I. Toxicologic, Biochemical and Histopathologic StudiesHepatology, 1984
- Valproic Acid and Metabolites: Pharmacological and Toxicological StudiesEpilepsia, 1984
- Abnormal metabolism of valproic acid in fatal hepatic failureEuropean Journal of Pediatrics, 1983
- A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrationsLife Sciences, 1981
- Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by gas chromatography—mass spectrometry using selected ion monitoringJournal of Chromatography B: Biomedical Sciences and Applications, 1981